How to build a loyal audience of brand evangelists.
In the ever-evolving landscape of healthcare, it's vital for organizations to take steps toward bridging the gap between their clinical and marketing teams.
New technology serves as reminder for the appropriate uses of CRISPR.
PerkinElmer Informatics’ Signals Solution Addresses Needs of Research and Clinical Scientists
Imaging is an integral part of many clinical studies, particularly in the fields of oncology and ophthalmology. Learn why imaging and centralized review are essential for clinical trials, how to address challenges that arise in these studies, and the advantages of partnering with MERIT in this video.
The next few years will require life science companies to bring consumer-facing digital services to the core of their corporate competence, rather than leaving it at the periphery of their business capabilities.
Curia is proud to partner with pharma and biotech companies to make new medicines that save lives. In order to be able to do that, Curia needs to be constantly innovating. In this podcast, you will learn from Curia’s VP of Portfolio and Sourcing, James Grabowski, about Curia’s small and large molecules most recent technologies, and capabilities.
The COVID-19 pandemic has shifted the adoption of digital platforms in pharma and has made the industry reconsider which technologies can improve global health moving forward.
Omnichannel marketing touts delivering efforts across all channels simultaneously, and looks to dethrone the incumbent multichannel marketing, but making the switch isn't exactly easy.
Embracing new digital-based tools is critical throughout the healthcare landscape to prepare for the rise of telemedicine as a permanent way of life.
Webinar Date/Time: Wed, Dec 7, 2022 2:00 PM EST
New mediums of technology must be utilized correctly to reap full benefits.
Importing drugs from Canada may increase the risk of US citizens being exposed to unsafe medicines.
An evolving system requires a focus on digital channels
Value-based price for access (VBPA) may increase access of specialty drugs for patients.
Adoption of digital by biopharma reps has added an element of flexibility to their engagement strategies, resulting in better communications with HCPs.
Omnichannel marketing bridges the gap from marketing operations to sales excellence. A well-planned, omnichannel marketing strategy allows pharma companies to reach the right people, at the right time, with the right message. Omnichannel marketing provides a holistic view of the customer to improve stakeholder experience across all touchpoints.
Life sciences professionals will need to keep up with market demand for biologics and biosimilars.
A robust market access strategy ensures that pharmaceutical products, including those with limited distribution, reach patients and are covered by diverse healthcare systems.
How pharmaceutical leaders at established companies can still disrupt the status quo and change the game.
Dr. Manuel Hermosilla shares his thoughts on how the pharmaceutical industry reacts to challenges that arise during trials, specifically during the search for an effective COVID-19 vaccine.
Findings from hundreds of interviews of exceptional pharma leaders around the world.
Harnessing the power of curiosity to position your next big idea
The profitability of biopharma drug launches in the US will remain in decline until manufacturers reimagine their approach with payers
How can pharmaceutical companies successfully apply advanced analytics? Pricing experts from Simon-Kucher & Partners identify the hurdles and winning approaches.
The 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.
A survey of 18 biopharmas, measuring their scope and implementation across key health equity dimensions and activities, uncovers useful context as companies seek better alignment of these goals with overall strategy.
Value-based price for access (VBPA) may increase access of specialty drugs for patients.